Vistin Pharma ASA VISTN

Vistin Pharma ASA (STU:VP4) navigates a 9% revenue dip with strong 66% gross margins, while advancing its new DC 95% product and securing long-term energy stability.

Oslo, Norway, 20 August 2026 Vistin Pharma ASA (VISTN) today announces its financial results for the second quarter and first half of 2026. Revenue in the second quarter amounted to MNOK 100, compared to MNOK 118 in Q2 2025. Sales volume increased by 8%, offset by a significantly stronger NOK against EUR in the quarter compared to 2025, impacting sales in local currency. Revenue for the first half of 2026 amounted to MNOK 212, compared to MNOK 233 in the corresponding period of 2025, representin

Oslo, Norway, 13 August 2026 Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results on Thursday 20th of August 2026. Vistin Pharma will host a conference call for all shareholders and other interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion. The second quarter conference call will be accessible via web and audio through the following access points: Webcast: https://edge.media-server.com/mmc/p/abe93pzc Telephone

Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter revenue of MNOK 112 with corresponding EBITDA of MNOK 27. Sales and EBITDA are slightly better than in the same quarter last year, adjusted for currency effects. Strong sales volume of 1.520MT in quarter (+9%), offset by stronger NOK vs EUR and lower global metformin prices compared to same quarter la